The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Target RWE, a leader in real-world evidence solutions in liver disease, presented important research on the use of ...

Discover a study in which liver dysmorphy was observed in 95% of patients with a high ANALI score, and it was significantly ...

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

The conditional marketing approval for Ocaliva (obeticholic acid) has been revoked with immediate effect, following a standoff between the EMA and Advanz Pharma Ltd., the company that markets the ...

Cour Pharmaceuticals plans to move its HQ out of Skokie for a custom-built, 50,000 square-foot space in Evanston Labs.

Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Read why GNFT stock's ...

Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

The London-based pharmaceutical company said that in cholestatic pruritus, also known as relentless itch, in primary biliary cholangitis, an autoimmune disease known as PBC, linerixibat showed a ...

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage ...